

OFFICE OF ENTERPRISE TECHNOLOGY SERVICES

P.O. BOX 119, HONOLULU, HAWAI'I 96810-0119 Ph: (808) 586-6000 | Fax: (808) 586-1922 ETS.HAWAII.GOV

January 20, 2021

The Honorable Ronald D. Kouchi, President, and Members of The Senate Thirty-First State Legislature Hawaii State Capitol, Room 409 Honolulu, Hawaii 96813

The Honorable Scott K. Saiki, Speaker, and Members of The House of Representatives Thirty-First State Legislature Hawaii State Capitol, Room 431 Honolulu, Hawaii 96813

Dear President Kouchi, Speaker Saiki, and Members of the Legislature:

Pursuant to HRS section 27-43.6, which requires the Chief Information Officer to submit applicable independent verification and validation (IV&V) reports to the Legislature within ten days of receiving the report, please find attached the report the Office of Enterprise Technology Services received for the State of Hawaii Department of Health Hawaii BHA Integrated Case Management System Project.

In accordance with HRS section 93-16, this report may be viewed electronically at http://ets.hawaii.gov (see "Reports").

Sincerely,

DOUGLAS MURDOCK Chief Information Officer

State of Hawai'i

Attachment (2)



Hawaii BHA Integrated Case Management System Project – *Phase 3*

Final IV&V Report for the period of

December 1 – December 31, 2020

Final submitted: January 11, 2021



Agenda

Executive Summary

IV&V Findings & Recommendations

Appendices

- A Rating Scales
- B Inputs
- C Project Trends





Executive Summary

The Project Team deployed Release 3.11 into production in December. As with previous releases, a subsequent mid-sprint deployment (MSD) is necessary to address/fix a few high priority production defects introduced as part of Release 3.11. This MSD is planned for January.

The RSM Team continued to provide essential support during December, alleviating some of the bandwidth concerns expressed by DOH to meet crucial project needs. BHA has received approval to pursue a State technical resource to help support on-going development work. IV&V continues to recommend that BHA seek additional state technical resources.

The Project continues to acknowledge the on-going quality issues/concerns and has taken steps to improve the quality assurance efforts for each release going forward.

The development of the IDM and Semantics Layer workstreams continue to progress and most of the technical hurdles causing schedule slippages have been resolved.

| Oct | Nov | Dec | Category | IV&V Observations | |
|---|---|---|--|-------------------|--|
| Sprint recommend BHA seek additional skilled technical MS Dynamics resources to permanently fill their technical support needs to assist with the increased volume. | | permanently fill their technical support needs to assist with the increased volume of work. The rating for this category remains a Yellow (medium criticality) for the December | | | |
| G | - I - I IISAF STORV I I | | IV&V reports no active findings for User Story (US) Validation category which remains Green (low criticality) for the December reporting period. IV&V will continue to monitor the US development and validation process in upcoming reporting periods. | | |
| Y | Planned for January to address R3.11 high-priority defects as well as other defe leftover R3.11 user stories. DOH and RSM agreed to defer R3.11 work items to due to insufficient testing time. IV&V continues to recommend the development automated regression test scripts. The criticality rating for this category remains | | The project deployed R3.11 to production in December. A mid-sprint deployment is planned for January to address R3.11 high-priority defects as well as other defects and leftover R3.11 user stories. DOH and RSM agreed to defer R3.11 work items to R3.12 due to insufficient testing time. IV&V continues to recommend the development of automated regression test scripts. The criticality rating for this category remains a Yellow (medium) for the December reporting period. IV&V will continue to monitor this category. | | |




Executive Summary

| Oct | Nov | Dec | Category | IV&V Observations | |
|-----|--|--|---|--|--|
| Y | Release / period. As with previous releases, deployment issues impacted R3.11 resulting in a subsequent mid-sprint deployment. IV&V has provided additional recommendation | | The criticality rating for this category remains Yellow (medium) for the December reporting period. As with previous releases, deployment issues impacted R3.11 resulting in a subsequent mid-sprint deployment. IV&V has provided additional recommendations to aid in improving future release deployments. IV&V will continue to monitor this category in January. | | |
| G | G | G | OJT and KT Sessions | The criticality rating for the OJT and KT Sessions category remains Green (low) for the December reporting period with no active findings. | |
| G | G | G | Targeted KT The Targeted KT criticality rating remains Green (low) for the December reporting period. The Project Team has commenced planning efforts for the KT sessions on Semantics Reporting and IDM tools. IV&V will continue to monitor this need moving forward. | | |
| G | G | deployment, the velocity for R3.10 far exceeded its original estimate. As a result, IV&V | | Although the project did not meet its planned velocity expectation for the R3.11 December deployment, the velocity for R3.10 far exceeded its original estimate. As a result, IV&V will keep the criticality rating for this category a Green (low) and will continue to monitor this category moving forward. | |
| G | G | G | Organizational Maturity Assessment | (low) The next OMA will be planned for March 2021 | |
| Y | Y | Y | Project Management | The criticality rating for the Project Management category remains Yellow (medium) in December. Quality and BHA Leadership bandwidth continues to remain a concern for IV&V, which we will be monitoring moving forward. The Project Team continues to fare well despite the COVID-19 pandemic. | |
| | | | | Both the procurement of the interactive training toolset to address DDD's OCM/Training priority resource needs and the BHA IAPDU were approved in December. | |



Executive Summary

As of the December 2020 reporting period, there are a total of nine open findings – four Medium Issues, two Medium Risks, and three Low Risks spread across the Sprint Planning, Release / Deployment Planning, Test Practice Validation, Targeted Knowledge Transfer, and Project Management assessment areas.





Assessment Categories

Throughout this project, IV&V will verify and validate activities performed in the following process areas:

- Sprint Planning
- User Story Validation
- Test Practice Validation
- Release / Deployment Planning
- On-the-Job Training (OJT) and Knowledge Transfer (KT) Sessions
- Targeted Knowledge Transfer (KT)
- Project Performance Metrics
- Organizational Maturity Assessment
- Project Management



Sprint Planning

| # | Key Findings | Criticality Rating |
|---|---|-----------------------|
| 8 | Medium Risk - The BHA Technical Team bandwidth may not be adequate to meet the needs of the project, which could compromise project productivity. BHA stated that although most vacant positions cannot be filled at this time, they have approval to fill a vacant IT Technician position. IV&V will continue to monitor this finding. | M |

| Recommendations | Status |
|--|-------------|
| The Project should investigate mechanisms of increasing the bandwidth of the BHA Technical Team, either by adding resources through new hires, or vendor contracts. | In progress |
| The Project should assess, where possible, if there are responsibilities of the BHA Technical Team that can be reassigned to other project staff. | In progress |
| The Project should evaluate where process inefficiencies can be addressed and streamlined to possibly free up the BHA Technical Team's availability. | In progress |
| The Project should consider the formation of a first level M&O resource team to triage/address production defects in a timely manner, without disrupting new development work. | In progress |
| The Project should consider procurement of an online training toolset to support OCM and technical efforts to offset the need for in-person training. | Complete |



Test Practice Validation

| # | Key Findings | Criticality Rating |
|---|---|-----------------------|
| 2 | Medium Issue – As a result of regression testing not being consistently performed, production releases are breaking and/or deprecating existing functionality in the production environment. Release 3.11 was promoted to production on 12/13/2020. The quality assurance and regression testing was rushed due to an incomplete deployment to test, which resulted in insufficient time to adequately test all functionality in the release from a business perspective prior to the planned deployment date. The project employed a risk-averse strategy that prioritized quality over schedule resulting in a much smaller release than originally planned. This created the need for another unplanned Mid Sprint Deployment in January to promote high priority functionality to production in advance of Release 3.12. Activities to automate regression testing continue to be delayed due to the lack of available staff to complete the initial setup. Since the project burn rate is expected to decrease after Release 3.12, DOH plans to concentrate on developing the setup efforts for automated regression test scripts to reduce the time needed for regression testing. | M |

| Recommendations | |
|--|-----------|
| Updating the regression test scripts to ensure consistency with system configuration. | Completed |
| Modifying release schedules to allow for regression testing timeframes. | Completed |
| Planning releases by functionality type to avoid unnecessary repetitive work being performed in any given section of the solution. | Completed |



Test Practice Validation (cont'd)

| Recommendations | Status |
|---|-------------|
| Performing regression testing after every release, or possibly every other release, or potentially tying regression tests to full solution upgrade releases. In addition, consider alternating the DDD and CAMHD scripts every other release. | In Progress |
| Modifying regression test scripts to start AFTER case creation, limiting the time it takes to execute. | Completed |
| Modifying the deployment scripts based on information gained from previous release deployments. | Completed |
| Pursuing additional formal training in AzureDevOps for test automation at the earliest possible juncture and commence efforts to automate at least the 2 primary regression test scripts. | Open |
| Consulting with RSM to determine how the 'interim testing processes' can be improved until such time that automated testing is available for repeatable and complete industry standard regression testing. | Completed |
| Implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed. | Completed |



Release / Deployment Planning

| # | Key Findings | Criticality Rating |
|---|---|-----------------------|
| 5 | Closed Medium Issue - Due to not following a detailed deployment script, the project may continue to experience defects related to deployment activities. IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. | Closed |

| Recommendations | Status |
|---|-----------|
| IVV recommends documenting deployment scripts for both the patch method and the full solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. | Completed |
| • Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment processes and instructions. | Completed |



Release / Deployment Planning

| # | Key Findings | Criticality Rating |
|----|---|-----------------------|
| 19 | New Medium Issue - Due to on-going deployment processes and technical execution issues, the project may continue to encounter defects and challenges in meeting projected timelines for production and non-production deployments. Release 3.11 was promoted to production on 12/13/2020. The promotion to the test environment for final testing and execution of regression test scripts prior to production deployment was missing software components. As a result, several user stories and defects were not tested as planned and were excluded from the production deployment. These items were subsequently re-prioritized to be resolved in a Mid Sprint Deployment in mid January or R3.12 in February. | M |

| Recommendations | |
|---|-------------|
| Develop a plan to institutionalize the execution of "Smoke Testing" for promotions to non-production and production environments. This will help to ensure that all components needed to test have been properly deployed prior to the actual execution of test activities. | New |
| Work in collaboration with RSM to establish a plan for DOH to assume all deployment activities to ensure complete ownership of these processes. This should assist with consistency in approach and execution going forward. | New |
| As appropriate, consult with RSM on best practices that BHA could employ to support deployment. | In Progress |
| Look at implementing 'hard' code freeze dates as well as test environment deployment dates to ensure that testing and deployment activities are not rushed. | Completed |



Release / Deployment Planning (cont'd)

| Recommendations | Status |
|---|-------------|
| Request the assistance of the RSM Solution Architect in reviewing and correcting issues associated with consistency of the configurations across environments, ensuring that the test environment is capable of testing ALL functions of any given release without the need for using multiple test environments. | In Progress |
| Request the assistance of the RSM Solution Architect in review of deployment scripts as a double check for accuracy and completeness prior to commencing deployment activities. | In Progress |
| Ensure an operational and fully functional test environment is available to effectively conduct end-to-end regression testing prior to deploying a release to production. | Completed |
| The Project Team should consider evaluating potential changes to improve/enhance existing processes and communications to address current release/deployment shortfalls. | In Progress |
| IV&V recommends performing a Root Cause Analysis in collaboration with RSM for the continued concerns surrounding environment differences. | In Progress |



Release / Deployment Planning (cont'd)

| # | Key Findings | Criticality Rating |
|----|---|-----------------------|
| 18 | Medium Issue – Due to consistent technical issues requiring escalation to Microsoft, the IDM and Semantic Layer project efforts are being delayed. While most of the issues requiring escalation to Microsoft were adequately addressed during December, the Azure Data Factory (ADF) 'first 10 rows missing data' issue remain open. BHA has created a work around for this issue while awaiting a permanent and reliable resolution from Microsoft. Additionally, the Project awaits the "Datalake" function fix from Microsoft to address a priority IDM issue. The fix was intended to be delivered the end of 2020 but that did not pan out. No new target date has been provided by Microsoft. IV&V will continue to monitor this issue in January. | M |

| Recommendations | Status |
|---|-------------|
| IV&V recommends the project to continue to monitor the status of outstanding Microsoft tickets and to escalate the priority of these tickets as deemed necessary. | In Progress |



Targeted KT

| # | Key Findings | Criticality Rating |
|----|--|-----------------------|
| 16 | Preliminary Concern – Use of Semantics and IDM for development and ongoing maintenance of the system requires BHA to take a proactive approach to learn and support these tools. IV&V is aware that an overview of the Semantics Layer KT session was held on 12/16/20. The planning effort will result in additional Semantic Layer and IDM KT sessions in the coming months. IV&V will continue to monitor this finding. | N/A |



Project Management

| # | Key Findings | Criticality Rating |
|----|--|-----------------------|
| 10 | Medium Risk -The COVID-19 pandemic and related "stay at home" order could hinder project activities and negatively impact the project schedule and budget. The project continued to maintain its ability to operate with staff working remotely. As previously reported, key project staff continue to have increases in participation of non-project activities to support the COVID-19 crisis. This includes the expedited development of a high priority D365 solution for Disease Tracking as well as the planning work for the expansion of the D365 environment to additional DOH business units. Aside from the Disease Tracking solution, IV&V notes that the CAMHD leadership time dedicated to the COVID-19 response declined during December. The HI Governor announced in late December that furloughs will be delayed due to the potential of the COVID Relief bill funding from the federal government. IV&V continues to note that there may also be future potential budget actions by the Governor which may affect the project due to projected State budget shortfalls. | M |

| Recommendations | Status |
|--|-------------|
| IV&V recommends BHA to ramp up efforts to setup, train, and assist stakeholders on remote work devices and tools and make every effort to help them to become highly functional with remote access technology (e.g. MS Teams/Skype). | Completed |
| IV&V recommends the project and DOH create a detailed, documented risk mitigation strategy and plan that is reviewed regularly and revised to address the current state of the COVID-19 threat and related impacts over the next 6 to 12 months. | In Progress |
| IV&V recommends updates to the OCM Plan to include any new activities or updates to planned activities to aid the organization through this COVID-19 situation in the short and long term. | Open |



| # | Key Findings | Criticality Rating |
|----|--|-----------------------|
| 15 | Medium Issue – Due to multiple quality concerns, the project may continue to face impactful system defects. BHA recognizes the impact of the quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior to development being initiated. IV&V will continue to monitor this medium priority project issue. | M |

| Recommendations | Status |
|---|-------------|
| Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. | In Progress |
| Perform typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. | In Progress |
| Assign dedicated resources to provide oversight of CAMHD Fiscal Processes. | In Progress |
| BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality. | Completed |
| Monitor implemented improvements for effectiveness. | In Progress |



| ; | # | Key Findings | Criticality Rating |
|---|----|---|-----------------------|
| 1 | 13 | Low Risk – PII/PHI data in non-production environments. BHA is still in the process of establishing a plan for managing PHI/PII data and plans to complete this effort in February after Release 3.12. IV&V will continue to monitor this finding. | L |

| Recommendations | Status |
|---|-------------------|
| IV&V recommends if production data is necessary in any non-production environment that DOH establish plan for effectively managing the security of the PII/PHI data, including the potential masking of data. | nes a In Progress |
| IV&V recommends that DOH mitigates this finding by removing and/or masking any PHI/PII data in its not production environments. | n- In Progress |



| # | Key Findings | Criticality Rating |
|----|--|-----------------------|
| 12 | Low Risk – DDD Project staffing shortages may have a continued negative effect on user adoption, training, and overall OCM activities. The contract to procure the interactive training toolset for onboarding new staff members and providers and to provide refresher training to existing staff members was successfully executed. Planning for the design of the necessary training will commence in January. Additionally, DDD has secured a contract for temporary Report Writing services. IV&V will continue to monitor. | L |

| Recommendations | Status |
|---|-------------|
| IV&V recommends that BHA does as much as possible within its sphere of influence to increase user adoption and training. This includes procurement of the online training toolsets to offset the need for in-person training, and adding staff as needed to support OCM and technical efforts. | In Progress |
| IV&V recommends DOH perform a detailed investigation of the specific variations as to how the system is currently being used by the user community. Consequently, users would be provided with constructive feedback on how the system should be utilized where gaps exist. This will likely lead to additional refresher training to close identified system knowledge gaps. | In Progress |



| # | Key Findings | Criticality Rating |
|----|--|-----------------------|
| 14 | Low Risk – Project unable to access activity logs. The planning effort for identifying the entities that will require activation of the new activity logs was completed during December. The implementation effort has been prioritized for inclusion in Release 3.12. IV&V will continue to monitor this finding until implemented. | • |

| Recommendations | Status |
|--|-------------|
| IV&V recommends that DHS continues to collaborate with Microsoft until the activity logging feature is | In Progress |
| available in all BHA non-production environments. | |



| # | Key Findings | Criticality Rating |
|----|---|-----------------------|
| 17 | Preliminary Concern – The bandwidth of CAMHD Leadership is being hampered by planning tasks and activities for assessing project expansion to other divisions. The planning effort for the expansion of the case management solution to the other DOH divisions continued during December. CAMHD Leadership continues to dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in the coming months. On the positive side, CAMHD leadership time dedicated to the COVID response decreased during December. IV&V will continue to monitor this concern. | N/A |



Project Performance Metrics

| Metric | Description | IV&V Observations | IV&V Updates |
|----------|--|---|--|
| Velocity | Review and validate the velocity data as reported by the project Verify the project is on pace to hit the total target number of US/USP for Phase 3 | December - Available velocity was estimated at 234 User Story Points (USPs) for Release 3.11. A total of 142 USPs were completed (approximately 61%). Overall, the cumulative Phase 3 targeted USPs through release 3.11 was planned for 738. The cumulative completed USPs total is currently 1096. | IV&V notes that there were a number of nearly-completed functionality items developed during R3.11 that did not get tested prior to the deployment Release date. It is anticipated that most of these will be included in either the Mid Sprint Deployment in January or Release 3.12 in February. This should help to make up the unanticipated USPs drop for the R3.11 production deployment. |

Project Performance Metrics (cont'd.)

| Metric | Description | IV&V Observations | IV&V Updates |
|-------------------------------------|--|--|--|
| US Point Estimates vs Actuals | Verify the project is tracking US Point estimates and actual data Determine the delta between estimates and actuals Based on the delta (if any) investigate the potential root cause for the delta | December - The Project Scrum Master closely tracks the USP daily. Determining the delta between USP estimates and actuals is a work in progress. | December – DDD and CAMHD have standardized a format for resources to track hours. The recording of resource hours is not completed by all team members making it difficult to calculate the variance between actual vs. projected hours. |



Project Performance Metrics (cont'd.)

| Metric | Description | IV&V Observations | IV&V Updates |
|----------------|---|---|--------------|
| Defect Metrics | Understand and track the following: Defects by category (bug fixes) US Points assigned to defects in a release vs US Points assigned to planned US in a release | December – Release 3.11 was comprised of 142 User Story Points that were released to production. 86% of the total USPs were associated with planned user stories and requests 14% of the total USPs were associated with defects from the backlog | N/A |

Organizational Maturity Assessment

Measure IV&V Observations

The Organizational Maturity Assessment (OMA) is updated on a bi-monthly basis. IV&V will plan the next OMA in March 2021.



Appendix A: IV&V Rating Scales

Appendix AIV&V Rating Scales

This appendix provides the details of each finding and recommendation identified by IV&V. Project stakeholders are encouraged to review the findings and recommendations log details as needed.

- See Findings and Recommendations Log (provided under separate cover)
- IV&V Assessment Category Rating Definitions

The assessment category is under control and the current scope can be delivered within the current schedule.

The assessment category's risks and issues have been identified, and mitigation activities are effective. The overall impact of risk and issues is minimal.

The assessment category is proceeding according to plan (< 30 days late).

The assessment category is under control but also actively addressing resource, schedule or scope challenges that have arisen. There is a clear plan to get back on track.



The assessment category's risk and/or issues have been identified, and further mitigation is required to facilitate forward progress. The known impact of potential risks and known issues are likely to jeopardize the assessment category. Schedule issues are emerging (> 30 days but < 60 days late).

Project Leadership attention is required to ensure the assessment category is under control.

The assessment category is not under control as there are serious problems with resources, schedule, or scope. A plan to get back on track is needed.



The assessment category's risks and issues pose significant challenges and require immediate mitigation and/or escalation. The project's ability to complete critical tasks and/or meet the project's objectives is compromised and is preventing the project from progressing forward.

Significant schedule issues exist (> 60 days late). Milestone and task completion dates will need to be re-planned. Executive management and/or project sponsorship attention is required to bring the assessment category under control.



Appendix A

Finding Criticality Ratings

| Criticality Rating | Definition |
|-----------------------|--|
| B | A high rating is assigned if there is a possibility of substantial impact to product quality, scope, cost, or schedule. A major disruption is likely, and the consequences would be unacceptable. A different approach is required. Mitigation strategies should be evaluated and acted upon immediately. |
| M | A medium rating is assigned if there is a possibility of moderate impact to product quality, scope, cost, or schedule. Some disruption is likely, and a different approach may be required. Mitigation strategies should be implemented as soon as feasible. |
| L | A low rating is assigned if there is a possibility of slight impact to product quality, scope, cost, or schedule. Minimal disruption is likely, and some oversight is most likely needed to ensure that the risk remains low. Mitigation strategies should be considered for implementation when possible. |





Appendix B

Inputs

This appendix identifies the artifacts and activities that serve as the basis for the IV&V observations.

Meetings attended during the December 2020 reporting period:

- Daily Scrum Meetings (selected)
- 2. Twice Weekly RSM Issues Meeting
- 3. Weekly BHA-ITS Project Status Meeting
- 4. Bi-Weekly Check-in: CAMHD
- Bi-Weekly Check-in: DDD
- 6. BHA IAPDU Planning Meeting
- 7. IV&V Draft IV&V Status Review Meeting with DOH
- IV&V Draft IV&V Status Review Meeting with RSM and DOH
- 9. GLRA #4 Meeting
- 10. R3.11 Deployment Planning Meeting

Eclipse IV&V® Base Standards and Checklists

Artifacts reviewed during the December 2020 reporting period:

- 1. Daily Scrum Notes (selected)
- 2. Twice Weekly Issues Meeting Notes (selected)





Appendix C: Project Trends

Appendix C Project Trends

| Trend: | Overall | l Projec | t Health | 1 | | | | | | | |
|------------------------------------|---------|----------|----------|-----|-----|-----|-----|-----|-----|-----|--|
| Dungana Awan | 2020 | | | | | | | | | | |
| Process Area User Story Validation | | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
| User Story Validation | | | | | | | | | | | |
| Test Practice Validation | | | | | | | | | | | |
| Sprint Planning | | | | | | | | | | | |
| Release / Deployment Planning | | | | | | | | | | | |
| OJT and KT Sessions | | | | | | | | | | | |
| Targeted KT | | | | | | | | | | | |
| Project Performance Metrics | | | | | | | | | | | |
| Organizational Maturity Metrics | | | | | | | | | | | |
| General Project Management | | | | | | | | | | | |
| | | | | | | | | | | | |
| Total Open Findings | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 10 | 11 | 11 | |
| Issue - high | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Issue - medium | 1 | 1 | 0 | 0 | 0 | 1 | 2 | 2 | 4 | 4 | |
| Issue - low | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Risk - high | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Risk - medium | 1 | 0 | 0 | 2 | 2 | 3 | 3 | 3 | 2 | 2 | |
| Risk - low | 3 | 4 | 3 | 2 | 1 | 0 | 0 | 0 | 3 | 3 | |
| Preliminary Concern | 0 | 0 | 1 | 1 | 1 | 3 | 3 | 5 | 2 | 2 | |



Solutions that Matter

| ID No | Identified Dat | Title | Observation | Significance | Recommendation | Updates | Process Area | Finding Type | Priority | Status | Closure Reason | Risk Owner |
|-------|-----------------------|--|--|-----------------------------|--|---|---------------------------|--------------|----------|--------|-----------------|--------------|
| 1.000 | 12/31/2019 | Detailed investigation into the project's sprint | IV&V is currently investigating the | While having a high level | As much as possible, the project should | 01/31/2020 - IV&V is closing this concern, and | Sprint Planning | Concern | N/A | Closed | Due to multiple | V Ramesh |
| | | planning processes and adoption of generally | following topics as they relate to | roadmap is good, the | identify what feature enhancements will be | will be tracking items related to Definition of | , , | | | | new items | |
| | | accepted agile best practices. | Sprint Planning and the project's | project should be able to | targeted for each Release and should clearly | Done, roadmap, resourcing, and backlog | | | | | being tracked | |
| | | | overall approach to agile software | identify what feature | map out the roadmap out through the last | grooming in new, separate findings. | | | | | at a more | |
| | | | development: | enhancements will be | Phase 3 release in September 2020. | | | | | | granular level, | |
| | | | - IV&V acknowledges that the project | targeted for each planned | Additionally, the project should clearly define | | | | | | this item has | |
| | | | is now planning three sprints outs, | release. This roadmap will | "Done" to ensure the project team is working | | | | | | been closed. | |
| | | | however, it appears that only a "high- | help the project manage | towards the same goal and increase | | | | | | Jeen dieseur | |
| | | | level" sprint planning roadmap has | scope and productivity. | opportunities for success. Having a clear | | | | | | | |
| | | | been produced, and it is unclear | Relatedly, the "definition | "definition of done" will help provide the | | | | | | | |
| | | | exactly how the project is targeting | done" is an important | project with guidance on how to stay within | | | | | | | |
| | | | , | artifact to ensure that the | , , | | | | | | | |
| | | | end of Mod 4. | project is successful. | scope. | | | | | | | |
| | | | | | | | | | | | | |
| | | | - IV&V is not aware of how the project | | | | | | | | | |
| | | | is currently defining "done" for Mod 3 | | | | | | | | | |
| | | | and Mod 4 | requests/enhancements | | | | | | | | |
| | | | Additionally, in the January 2020 | and manage scope. | | | | | | | | |
| | | | reporting period, IV&V will seek | | | | | | | | | |
| | | | additional information and visibility | | | | | | | | | |
| | | | into the project's processes specific to | | | | | | | | | |
| | | | prioritizing requests and how user | | | | | | | | | |
| | | | stories in TFS are tagged to features, | | | | | | | | | |
| | | | as well as the realignment of project | | | | | | | | | |
| | | | development and configuration | | | | | | | | | |
| | | | resources to complete the scope of | | | | | | | | | |
| | | | Release 3.5. | | | | | | | | | |
| 2.000 | 12/31/2019 | As a result of regression testing not being | R3.3 introduced a defect that | Thorough vetting and | To address regression testing, the Project | 12/31/2020 - Release 3.11 was promoted to | Test Practice Validation | Issue | Medium | Open | | D Macdonald |
| 2.000 | | consistently performed, production releases | deprecated features in production | validation of regression | should continue to pursue and/or consider: | production on 12/13/2020. The quality | rest i factice validation | 13300 | iviculum | Орен | | Diviacuonalu |
| | l I | are both breaking and deprecating existing | | - | Updating the regression test scripts to | assurance and regression testing was rushed | | | | | | |
| | l I | functionality in the production environment. | Trajectory functionality. DDD has | prevent both defects and | | , , | | | | | | |
| | | runctionality in the production environment. | informed IV&V that there are other | the deprecation of | - Completed | resulted in insufficient time to adequately test | | | | | | |
| | | | | 1 | | | | | | | | |
| | | | examples of functionality being | production functionality | Modifying release schedules to allow for regression testing timeframes - Completed | all functionality in the release from a business | | | | | | |
| | | | deprecated after a release, some of | when a release is pushed | | perspective prior to the planned deployment | | | | | | |
| | | | which are still being investigated. As | | 3. Grouping releases by functionality type to | date. The project employed a risk-averse | | | | | | |
| | | | of this report, IV&V has not evaluated | production, the project | avoid unnecessary repetitive work being | strategy that prioritized quality over schedule | | | | | | |
| | | | the project's root cause analysis (RCA) | | performed in any given section of the | resulting in a much smaller release than | | | | | | |
| | | | process used to determine why such | and repeatable process for | · · | originally planned. This created the need for | | | | | | |
| | | | functionality was deprecated but will | determining the root | 4. Performing regression testing after every | another unplanned Mid Sprint Deployment in | | | | | | |
| | | | discuss further with BHA in January | cause of the problem. | release, or possibly every other release, or | January to promote high priority functionality to | '[| | | | | |
| | | | 2020. | | potentially tying regression tests to full | production in advance of Release 3.12. | | | | | | |
| | | | | | solution upgrade releases. In addition, | Activities to automate regression testing | | | | | | |
| | | | | | consider alternating the DDD and CAMHD | continue to be delayed due to the lack of | | | | | | |
| | | | | | scripts every other release - In Progress | available staff to complete the initial setup. | | | | | | |
| | | | | | 5. Modifying regression test scripts to start | Since the project burn rate is expected to | | | | | | |
| | | | | | · - | decrease after Release 3.12, DOH plans to | | | | | | |
| | | | | | to execute - Completed | concentrate on developing the setup efforts for | | | | | | |
| | | | | | 6. Modifying the deployment scripts based | automated regression test scripts to reduce the | | | | | | |
| | | | | | on information gained from previous release | time needed for regression testing. | | | | | | |
| | | | | | deployments - Completed | 11/30/2020 - Release 3.10 was promoted to | | | | | | |
| | | | | | 7. Pursuing additional formal training in | production on 11/11/2020. Approximately nine | | | | | | |
| | | | | | AzureDevOps for test automation at the | (9) new defects were identified after the | | | | | | |
| | | | | | earliest possible juncture and commence | deployment. Root causes are suspected to be a | | | | | | |
| | | | | | efforts to automate at least the 2 primary | combination of insufficient testing from a | | | | | | |
| | | | | | regression test scripts - Open | business perspective coupled with deployment | | | | | | |
| | | | | 1 | 1 0 | 1 | 1 | 1 | | | | |

| 3.000 | 12/24/2040 | l., | Invavi 1: 5 1 2040 il i | lo | 1 200 | 00/04/0000 0/000 | Lor | Dist. | 1 | 61 I | Inc. 41 | 5.4 1 11 |
|-------|------------|---|--|--|---|---|--------------------------------|-------|--------|--------|--|-------------|
| 3.000 | 12/31/2019 | Usage of open source JavaScript framework | IV&V learned in December 2019 that | Open source tools and frameworks offer | IV&V recommends BHA work to establish a | 08/31/2020 - IV&V is unaware of any additional KT gaps being identified by DOH, and as such, is | Targeted KT | Risk | Low | Closed | RSM has successfully | D Macdonald |
| | | for development and ongoing maintenance of | the Calculator 3.0 functionality is built | | reliable and repeatable process for keeping | | | | | | , | |
| | | Calculator 3.0 requires BHA to take a proactive | 1 ' ' | organizations great | abreast of communal updates and support | closing this finding. | | | | | held several KT | |
| | | approach to support and security. | framework. As this framework is | opportunities to build and | 1 | 07/24/2020 The Desired week had the goal with | | | | | sessions for | |
| | | | relatively new, the open source | configure customized | Completed | 07/31/2020 - The Project resolved the majority | | | | | this technology | |
| | | | support community is small. IV&V's | solutions at lower costs | IV&V recommends BHA continue to hold | of the outstanding Calculator 3.0 defects during | | | | | and | |
| | | | concerns include: | than through software | targeted KT sessions with RSM on | July which was implemented in the mid-sprint | | | | | functionality, | |
| | | | - The availability of reliable support | purchase or licensing. | maintaining Calculator 3.0 via a suite of tools, | release on 7/17/2020. The final Calculator 3.0 | | | | | and DOH staff | |
| | | | for Vue.JS | However, open source | and determine what additional skillsets, | Knowledge Transfer session was conducted on | | | | | have stated | |
| | | | - The project's understanding of any | tools and frameworks | training, and/or resources are needed to | 7/17/2020. IV&V recommends BHA to identify | | | | | that it was well | |
| | | | known vulnerabilities with Vue.JS, and | often do not come with | support BHA's long-term ownership of | and communicate any additional KT gaps to | | | | | received. | |
| | | | development of a process to remain | support models, other | Calculator 3.0 - Completed | RSM during the month of August. If no | | | | | | |
| | | | current on vulnerabilities discovered | than those offered | | additional needs are identified, IV&V will close | | | | | | |
| | | | by the support community. | through the tool's | | this finding. | | | | | | |
| | | | - The RSM lead for Calculator 3.0 went | community. Because of | | 06/30/2020 - The project continued to focus | | | | | | |
| | | | on extended parental leave in | this, the organization | | attention on the Calculator 3.0 defects during | | | | | | |
| | | | December 2019 | bears the weight of | | the month of June. RSM conducted another | | | | | | |
| | | | IV&V acknowledges that BHA has | seeking out reliable help | | Calculator 3.0 Knowledge Transfer session on | | | | | | |
| | | | downloaded Vue.JS to start getting | and support, as well as | | 6/26/2020 and scheduled a final session for | | | | | | |
| | | | familiar with it. | much take a proactive | | 7/17/2020. | | | | | | |
| | | | | approach to security and | | , , | | | | | | |
| | | | | identifying any | | 05/31/2020 - The project continued to focus | | | | | | |
| | | | | vulnerabilities in the tools. | | attention on the Calculator 3.0 user stories and | | | | | | |
| | | | | vuiller abilities in the tools. | | defects during the month of May. RSM | | | | | | |
| | | | | | | , | | | | | | |
| | | | | | | conducted another Calculator 3.0 Knowledge | | | | | | |
| | | | | | | Transfer session on 5/29/2020 which IV&V | | | | | | |
| | | | | | | attended. This session included the new C3.0 | | | | | | |
| | | | | | | year-end changes. Additional KT sessions is | | | | | | |
| | | | | | | , , | | | | | | |
| 5.000 | 1/31/2020 | Due to the project not following a detailed | There have been several defects | A complete, up to date, | IVV recommends documenting deployment | 12/31/2020 - IV&V has closed this issue as the | Release/Deployment | Issue | Medium | Closed | Key finding has | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue | pushed to production with Phase 3 | and documented | scripts for both the patch method and the ful | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been | Release/Deployment Planning | Issue | Medium | Closed | been | D Macdonald |
| 5.000 | 1/31/2020 | | | 1 ' ' ' ' ' | 9 . , | 12/31/2020 - IV&V has closed this issue as the | | Issue | Medium | Closed | been addressed and | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue | pushed to production with Phase 3 | and documented | scripts for both the patch method and the ful | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been | | Issue | Medium | Closed | been | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects | and documented deployment script is | scripts for both the patch method and the ful solution upgrade method. The script(s) | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding | | Issue | Medium | Closed | been addressed and | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been | and documented deployment script is needed to ensure the | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing | | Issue | Medium | Closed | been addressed and proposed IV&V | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental | and documented deployment script is needed to ensure the repeatability and stability | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these | and documented deployment script is needed to ensure the repeatability and stability of DOH's production | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has been created | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has been created to address on- going | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has been created to address on- going deployment | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has been created to address on- going deployment processes and | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has been created to address on- going deployment processes and technical | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has been created to address on- going deployment processes and technical execution | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has been created to address on- going deployment processes and technical | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has been created to address on- going deployment processes and technical execution | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has been created to address on- going deployment processes and technical execution | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has been created to address on- going deployment processes and technical execution | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has been created to address on- going deployment processes and technical execution | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has been created to address on- going deployment processes and technical execution | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has been created to address on- going deployment processes and technical execution | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. 10/31/2020 - The RSM and DOH Teams have | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has been created to address on- going deployment processes and technical execution | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has been created to address on- going deployment processes and technical execution | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. 10/31/2020 - The RSM and DOH Teams have | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has been created to address on- going deployment processes and technical execution | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. 10/31/2020 - The RSM and DOH Teams have collaborated to develop a detailed Production | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has been created to address on- going deployment processes and technical execution | D Macdonald |
| 5.000 | 1/31/2020 | deployment script, the project may continue to experience defects related to deployment | pushed to production with Phase 3 releases. Some of the defects introduced to production have been narrowed down to environmental promotional activities. In these instances, the DEV and TEST environments were not in sync with the production environment (missing business rules, missing components, missing dependencies, etc.). IVV is aware that DOH staff shadowed RSM staff for all deployment releases during Phase 2 with RSM providing instruction and DOH staff physically executing the tasks and activities via keyboard. For Phase 3, it is unclear whether a complete, up to date, and documented deployment script, or deployment notes, are being utilized | and documented deployment script is needed to ensure the repeatability and stability of DOH's production deployments. Since there are currently two deployment types (patches and full solution upgrades), two scripts may be warranted. An embedded process and documented script will help ensure that mistakes are minimized, and that functionality is not mistakenly deprecated when deployments take | scripts for both the patch method and the ful solution upgrade method. The script(s) should be in the form of a step-by-step procedure that walks through from start to finish of the deployment process and involve several technical staff to ensure staff availability to accomplish these tasks when primary deployment personnel are unavailable. Standardize the content of all developer deployment task notes, with a goal of eliminating any potential ambiguity to the Deployment Team, resulting in a cleaner and more repeatable set of deployment | 12/31/2020 - IV&V has closed this issue as the related recommendations below has been completed. A subsequent medium issue finding (#19) has been opened to address ongoing deployment processes and technical execution issues. 11/30/2020 - Release 3.10 was promoted to production on 11/11/2020. Approximately nine (9) new defects were identified after the deployment. Root causes are suspected to be a combination of insufficient testing from a business perspective coupled with deployment issues. A bulk record update task required as part of the implementation was not included in the deployment, resulting in contacts being deprecated from the Circle of Support in Inspire. It is unclear if any other deployment issues may have also contributed to the new defects. Deployment corrections were applied in a mid sprint release on 11/27/2020. Based on the recurrence of this finding, IV&V has changed this Risk to an Issue and will continue to monitor until resolved. 10/31/2020 - The RSM and DOH Teams have collaborated to develop a detailed Production Deployment Guide for R3.10 and are in the | | Issue | Medium | Closed | been addressed and proposed IV&V recommendati ons have been completed. A subsequent finding #19 has been created to address on- going deployment processes and technical execution | D Macdonald |

| | 31/2020 The project lacks a documented 'Definition of Done", which could challenge the project's ability to fully achieve the goals of Phase 3. | 'Definition of Done' (DOD) for the BHA Top 100 User Stories of for Phase 3. Because of this, it is unclear how proposed functionality/features are prioritized for each sprint, and throughout Phase 3. | Project's vision, business, and technical goals that are important inputs for stakeholders to develop a Roadmap for Phase 3. Without the 'Definition of Done' document, the project is likely to struggle to prioritize proposed functionality/features which may be equally important but are at odds with each other. | Project is currently in the process of creating the Definition of Done. IV&V recommends that the project create this document and socialize this with project team before end of Feb 2020 IV&V recommends that the project consider the items from the prioritized list, available resources and define "Done" as a percentage of the identified priority list with room for flexibility to add any other features/enhancements that will be identified during Phase 3. | Definition of Done, adjusting as/if necessary. IV&V will continue to monitor the project's adherence to Definition of Done and progress against it but is closing out this concern as of the February report. | Project Management | Concern | N/A | Closed | Definition of Done completed and socialized. | V Ramesh |
|-----------|---|--|---|---|---|--------------------|---------|-----|--------|--|-------------|
| 7.000 1/3 | tal/2020 The lack of consistent backlog grooming could result in the project backlog having obsolete, non-estimated, and poorly defined user stories. | If the backlog of defects, requests, and user stories continues to grow. Currently, there are approximately 429 defects and requests, of which almost 200 have a status of 'New'. IVV notes that a large percentage of the backlogged work items do not have user story points estimated. Many of the items listed in the backlog are old, and some may have had needs or requirements change over time or may now be obsolete. IV&V notes that DDD and CAMHD have initiated this effort and agreed to prioritize grooming the backlog by the end of February. | is carrying work items that may not ever be completed for any reason, they should be removed from the backlog to ensure its viability. | fully defined, readying them for | 1 - | Project Management | Risk | Low | Closed | The project has demonstrated they are consistently grooming the backlog. | D Macdonald |

| 8.000 | 1/31/2020 | The RHA Technical Team handwidth may not | The BHA Technical Team plays a role | The RHA Technical Team | The Project should investigate mechanisms | 12/31/2020 - BHA stated that although most | Sprint Planning | Risk | Medium | Open | | D Macdonald |
|-------|-----------|--|---|--|---|--|--------------------|---------|--------|--------|---|-------------|
| 8.000 | | The BHA Technical Team bandwidth may not be sufficient to meet the needs of the project, which could compromise project productivity. | The BHA Technical Team plays a role that is critical to project success. Currently, the responsibilities associated with the BHA Technical Team have expanded beyond their collective available bandwidth. IV&V notes that BHA began addressing this bandwidth issue, which includes increased collaboration with key RSM resources, and are working to potentially change the structure of the Technical Team. | project. As such, the Team's time is both extremely valuable and scarce. If the Team's expected workload exceeds bandwidth, the project could experience | manner, without disrupting new development work. The Project should consider procurement of an online training toolset to support OCM | 12/31/2020 - BHA stated that although most vacant positions cannot be filled at this time, they have approval to fill a vacant IT Technician position. IV&V will continue to monitor this finding. 11/30/2020 - There were no substantive changes to this finding in November. IV&V will continue to monitor. 10/31/2020 - There were no substantive changes to this finding during October. IVV will continue to monitor. 10/30/2020 - There were no substantive changes to this finding during September. IV&V will continue to monitor. 10/31/2020 - There were no substantive changes to this finding during September. IV&V will continue to monitor. 10/31/2020 - There were no substantive changes to this finding during August. IVV will continue to monitor. 10/31/2020 - For Release 3.10, BHA continues to rely on the RSM Technical Team for Solution Architect and Technical Team support. While this is clearly a positive move to increase bandwidth of the BHA Technical Architect and team for the short term, the volume of work for this team continues to exceed existing capacity and may be contributing to ongoing deployment and code promotion issues. IV&V is raising the rating for this risk from low to medium and will continue to monitor this | Sprint Planning | Risk | Medium | Open | | D Macdonald |
| 9.000 | 1/31/2020 | The lack of a Product Roadmap that provides direction on the top product features to be delivered in the near term (next 3 months), midterm, and long term could have an adverse impact on the Project's scope and schedule. | BHA does not have a single, definitive Product Roadmap for Phase 3 that addresses the functionalities, features, and / or enhancements to be built in order to fully address BHA's business needs. IV&V met with RSM and BHA on this topic in January, and notes that the project is actively working to address this concern. | guides an agile project on what functionalities/features are targeted to be built and released and when | the Project complete this by the end of February 2020 to understand if there are any constraints (resources, budget) that may | 02/29/2020 - In February, the project further defined the Phase 3 Product Roadmap and aligned it with the Phase 3 Definition of Done. IV&V recommends the project continually review and update both the Product Roadmap and Definition of Done, adjusting as necessary. IV&V will continue to monitor the project's adherence to the Product Roadmap and progress against it but is closing out this concern as of the February report. | Project Management | Concern | N/A | Closed | Product Roadmap aligned with Definition of Done | V Ramesh |

| 10.000 | 3/31/2020 | The COVID-19 pandemic and the related "stay | On 3/23/2020, the Governor issued a | DOH stakeholder | - IV&V recommends BHA to ramp up efforts | 12/31/2020 - The project continued to maintain | Project Management | Risk | Medium | Open | ln. | Macdonald |
|--------|-------------|--|--|---|---|---|-----------------------|---------|----------|--------|-----------------|-------------|
| 10.000 | | at home" order could hinder project activities | "stay at home, work from home | participation in key | to setup, train, and assist stakeholders on | its ability to operate with staff working | Froject ivialiagement | Misk | iviculum | Ореп | ا | iviacuonalu |
| | | and negatively impact the project schedule | order" that has reduced state | activities could be | remote work devices and tools and make | remotely. As previously reported, key project | | | | | | |
| | | and budget. | departments ability to be fully | significantly hindered, not | | staff continue to have increases in participation | | | | | | |
| | | and budget. | functional as the large majority of | only by required remote | functional with remote access technology | of non-project activities to support the COVID- | | | | | | |
| | | | state workers will be required to work | 1 ' ' ' | (e.g. MS | 19 crisis. This includes the expedited | | | | | | |
| | | | from home/remotely at least until the | 1 | Teams/Skype) - Completed | development of a high priority D365 solution | | | | | | |
| | | | end of April and some offices may be | activities that could occur | - IV&V recommends the project and DOH | for Disease Tracking as well as the planning | | | | | | |
| | | | completely shut down until that time | as the department could | create a detailed, documented risk mitigation | work for the expansion of the D365 | | | | | | |
| | | | as well. Unclear if the order will | become overwhelmed | strategy and plan that is reviewed regularly | environment to additional DOH business units. | | | | | | |
| | | | extend beyond that date. | processing and providing | and revised to address the current state of | Aside from the Disease Tracking solution, IV&V | | | | | | |
| | | | exteria beyona triat date. | services due to the | | notes that the CAMHD leadership time | | | | | | |
| | | | | resulting economic | the next 6 to 12 months - In Progress | dedicated to the COVID-19 response declined | | | | | | |
| | | | | impacts to citizens. Some | _ | during December. The HI Governor announced | | | | | | |
| | | | | 1 ' | | - | | | | | | |
| | | | | stakeholders may be | to include any new activities or updates to | in late December that furloughs will be delayed | | | | | | |
| | | | | unable (due to stricter shutdown policies) or | planned activities to aid the organization through this COVID-19 situation in the short | due to the potential of the COVID Relief bill funding from the federal government. IV&V | | | | | | |
| | | | | | | | | | | | | |
| | | | | unwilling to perform these activities during this | and long term - Open | continues to note that there may also be future | | | | | | |
| | | | | chaotic time. Planned SI | | potential budget actions by the Governor which | | | | | | |
| | | | | | | may affect the project due to projected State | | | | | | |
| | | | | on-site visits will also likely | | budget shortfalls. | | | | | | |
| | | | | be changed to remote | | 11/30/2020 - The project has maintained its | | | | | | |
| | | | | which could reduce the | | ability to operate with staff working remotely. | | | | | | |
| | | | | effectiveness of their | | As previously reported, key project staff | | | | | | |
| | | | | project activities. Going | | continue to have increases in participation of | | | | | | |
| | | | | forward most if not all | | non-project activities to support the COVID-19 | | | | | | |
| | | | | project activities will more | | crisis. IV&V continues to note that there may | | | | | | |
| 44.000 | 5 /04 /0000 | | | than likely be conducted | | also be future potential budget actions by the | | | | | | |
| 11.000 | 5/31/2020 | The lack of design reviews for complex user | There were a couple incidents during | 1 ' | IV&V recommends (and DOH has | 07/31/2020 - The Project continues to to spend | | Concern | | Closed | This process | |
| | | stories has resulted in the promotion of | May where the code promoted to | functional design are not | commenced) conducting technical design | additional time on the designs of complex user | | | | | change to | |
| | | incomplete solutions into production. | production did not fully meet all | met, users could | reviews for complex user stories prior to | stories during June to ensure requirements and | | | | | spend extra | |
| | | | requirements of associated user | 1 ' | development to ensure designs are complete | user story components were fully captured in | | | | | time on the | |
| | | | stories for CAMHD Progress Notes. | complete required | and all requirements associated with the | design sessions. This process change has proven | | | | | design of | |
| | | | The components that were developed | l | design are met. IV&V observed this activity | successful, and as such, IV&V recommends | | | | | complex user | |
| | | | and implemented were functional, | incomplete data collection | has been implemented by DOH in the month | closing this concern. | | | | | stories to | |
| | | | however the effort was complicated | and potential issues in | of May. | 06/30/2020 - IV&V acknowledges the Project | | | | | ensure that all | |
| | | | by additional requirements being | service delivery. | | Team continued to spend additional time on the | | | | | requirements | |
| | | | added during development that | | | designs of complex user stories during June to | | | | | are | |
| | | | necessitated additional changes to the | | | ensure requirements and user story | | | | | represented | |
| | | | design. IV&V will continue to monitor | | | components were fully captured in design | | | | | has proven to | |
| | | | the design review activity for large | | | sessions. IV&V will continue to monitor in July. | | | | | be successful. | |
| | | | user stories moving forward | | | | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | | | | | | |

| 12.0 | 7/21/2020 | DDD Due is at staffing a houteness many house | The mean adoption and training offerte | The significance and | IN (8) / was a second a that BLIA do so so wough as | 13/31/3030 The sentreet to presure the | Duniont Management | Risk | Low | 0 | D Macdonald |
|------|--------------|---|---|--|---|--|--------------------|------|-----|------|---------------|
| 12.0 | 7/31/2020 | DDD Project staffing shortages may have a continued negative effect on user adoption, | The user adoption and training efforts are hampered based on staffing | impact of OCM can never | IV&V recommends that BHA does as much as possible within its sphere of influence to | 12/31/2020 - The contract to procure the interactive training toolset for onboarding new | Project Management | NISK | LOW | Open | Diviaccionalc |
| | | training, overall OCM activities. | shortages. DDD has stated that its | be understated. It is | increase user adoption and training. This | staff members and providers and to provide | | | | | |
| | | training, overall Ocivi activities. | users have been found to not be | clearly a best practice that | | refresher training to existing staff members was | | | | | |
| | | | utilizing the system to its fullest extent | 1 ' ' | toolsets to offset the need for in-person | | | | | | |
| | | | in terms of system workflow, provide | the solution in the same | training, and adding staff as needed to | successfully executed. Planning for the design of the necessary training will commence in | | | | | |
| | | | their insights and input, follow up, etc. | | | January. Additionally, DDD has secured a | | | | | |
| | | | To assist in OCM activities, DDD has | | | * ** | | | | | |
| | | | defined the need for an interactive | 1 ' | IV&V recommends DOH perform a detailed | contract for temporary Report Writing services. | | | | | |
| | | | | users is likely to cause variations in data | investigation of the specific variations as to | IV&V will continue to monitor. | | | | | |
| | | | training tool to support Inspire. | | how the system is currently being used by | 11/30/2020 - Procurement of the interactive | | | | | |
| | | | | collection and analytical efforts using the data | the user community. Consequently, users | training toolset for onboarding new staff | | | | | |
| | | | | 1 | would be provided with constructive | members and providers and to provide | | | | | |
| | | | | collected. | feedback on how the system should be | refresher training to existing staff members is | | | | | |
| | | | | | utilized where gaps exist. This will likely lead | currently pending RSM agreement of terms and | | | | | |
| | | | | | to additional refresher training to close | subsequent completion of an MOU. This is | | | | | |
| | | | | | identified system knowledge gaps. | expected to be finalized in December. DOH has | | | | | |
| | | | | | | also posted a procurement request for Report | | | | | |
| | | | | | | Writing services, and the end date for the posting is 11/30/2020. Lastly, DOH is | | | | | |
| | | | | | | considering the addition of a technical | | | | | |
| | | | | | | | | | | | |
| | | | | | | deployment specialist for the project, however this procurement has not yet been released. | | | | | |
| | | | | | | IV&V will continue to monitor. | | | | | |
| | | | | | | | | | | | |
| | | | | | | 10/31/2020 - To assist in OCM activities, DDD | | | | | |
| | | | | | | has submitted a draft Agreement of Services to procure an interactive training toolset for | | | | | |
| | | | | | | onboarding new staff members and providers | | | | | |
| | | | | | | and to provide refresher training to existing | | | | | |
| 13.0 | 00 8/31/2020 | PII/PHI data in non-production environments | IV&V has been made aware that | Failure to secure PII/PHI | IV&V recommends if production data is | 12/31/2020 - BHA is still in the process of | Project Management | Risk | Low | Open | D Macdonald |
| 13.0 | 0/31/2020 | rii/riii data iii noii-production environments | PII/PHI data currently exist in a non- | data leaves the | necessary in any non-production | establishing a plan for managing PHI/PII data | rioject Management | Misk | LOW | Ореп | Diviacuonalu |
| | | | production environment to meet | organization open to | environment that DOH establishes a plan for | and plans to complete this effort in February | | | | | |
| | | | project needs. Generally this is not a | highly targeted social | effectively managing the security of the | after Release 3.12. IV&V will continue to | | | | | |
| | | | good security practice as the presence | 0 , 0 | PII/PHI data, including the potential masking | monitor this finding. | | | | | |
| | | | of PII/PHI data in non-production | regulatory fines, and loss | of data. | 11/30/2020 - DOH is still in the process of | | | | | |
| | | | 1 . | of client trust and loyalty. | IV&V recommends that DOH mitigates this | establishing a plan for managing PHI/PII data | | | | | |
| | | | for theft, loss or exposure thus | | finding by removing and/or masking any | and plans to complete this effort in December. | | | | | |
| | | | increasing the organization's risk. | | PHI/PII data in its non-production | Due to the security nature of PHI/PII data, IV&V | | | | | |
| | | | Failure to secure PII/PHI data leaves | | environments. | has escalated this finding from a preliminary | | | | | |
| | | | the organization open to highly | | | concern to a low priority risk and will continue | | | | | |
| | | | targeted social engineering attacks, | | | to monitor this finding. | | | | | |
| | | | heavy regulatory fines, and loss of | | | 10/31/2020 - DOH is still in process of | | | | | |
| | | | client trust and loyalty. | | | establishing a plan for managing PHI/PII data. | | | | | |
| | | | | | | IV&V will continue to monitor this finding. | | | | | |
| | | | | | | 09/30/2020 - DOH recognizes this concern and | | | | | |
| | | | | | | is in the process of establishing a plan to | | | | | |
| | | | | | | manage this data. When completed, this plan | | | | | |
| | | | | | | will include reducing the volume of PHI/PII data | | | | | |
| | | | | | | in non-production environments as well as | | | | | |
| | | | | | | mask PHI/PII data that is required for project | | | | | |
| | | | | | | activities. IV&V will continue to monitor this | | | | | |
| | | | | | | preliminary data security concern. | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |

| 14.000 | 0/24/2020 | la | | | Invava | 10 /04 /0000 TI I : 55 .5 .1 .15 : | la 1 /a 1 . | Int. I. | 1 | | 1. | |
|--------|-----------|---|--|---|--|--|--------------------|---------|--------|------|----|--------------------|
| 14.000 | 8/31/2020 | Project not able to access Activity Logs | The Project recently deployed audit | The unavailability of | IV&V recommends that DHS continues to collaborate with Microsoft until the activity | 12/31/2020 - The planning effort for identifying the entities that will require activation of the | Planning | Risk | Low | Open | | D Macdonald |
| | | | log functionality into production whereby these logs can be accessed | activity logs may hamper the investigation of future | logging feature is available in all BHA non- | • | Pidililing | | | | | |
| | | | · · · | _ | | new activity logs was completed during | | | | | | |
| | | | and exported as needed. However, | security breaches. | production environments. | December. The implementation effort has been | | | | | | |
| | | | IV&V was made aware access to | | | prioritized for inclusion in Release 3.12. IV&V | | | | | | |
| | | | activity logging for users with just view | | | will continue to monitor this finding until | | | | | | |
| | | | permissions will not be available from | | | implemented. | | | | | | |
| | | | Microsoft in the public sector | | | 11/30/2020 - The DOH technical team has | | | | | | |
| | | | environment until the end of | | | commenced the analytical effort to determine | | | | | | |
| | | | September 2020. The unavailability of | | | which entities to activate the logging features | | | | | | |
| | | | these specific activity logs could | | | for, as well as which entities will not require this | | | | | | |
| | | | potentially hamper the investigation | | | action. IV&V will continue to monitor this | | | | | | |
| | | | of future security events until | | | finding until successfully implemented. | | | | | | |
| | | | implemented. | | | 10/31/2020 - Microsoft's implementation of | | | | | | |
| | | | | | | the optional components of the logging features | | | | | | |
| | | | | | | remain scheduled for 10/31/2020. IVV will | | | | | | |
| | | | | | | continue to monitor the implementation of | | | | | | |
| | | | | | | these features in the DOH non-production | | | | | | |
| | | | | | | environments during November. | | | | | | |
| | | | | | | | | | | | | |
| | | | | | | 09/30/2020 - DOH reported that Microsoft's | | | | | | |
| | | | | | | implementation of the logging features is split | | | | | | |
| | | | | | | between mandatory and non-mandatory | | | | | | |
| | | | | | | components. The mandatory components were | | | | | | |
| | | | | | | released by Microsoft during the week of | | | | | | |
| | | | | | | 9/14/2020, and the rollout of this functionality | | | | | | |
| | | | | | | is currently in process for DOH's non-production | | | | | | |
| | | | | | | environments. Release of the optional | | | | | | |
| 15.000 | 0/20/2020 | | | | | | | 1. | | | | D Mandanald |
| | 3/30/2020 | Due to multiple quality concerns, the project | System defects identified in August | The identified quality | To address quality issues, the Project should | 12/31/2020 - BHA recognizes the impact of the | Project Management | Issue | Medium | Open | [| D Macdonald |
| | 3/30/2020 | may continue to face impactful system | System defects identified in August that affected claims were due to multi- | 1 ' ' | To address quality issues, the Project should continue to pursue and/or consider: | 12/31/2020 - BHA recognizes the impact of the quality concerns and has initiated weekly | Project Management | Issue | Medium | Open | | Diviaccionalc |
| | 3/30/2020 | 1 | 1 ' | 1 ' ' | 1 | _ · | Project Management | Issue | Medium | Open | | Diviaccionalci |
| | 9/30/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were | issues have negatively | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance | quality concerns and has initiated weekly meetings with the development and test teams | Project Management | Issue | Medium | Open | | Diviaccionalci |
| | 3/30/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this | issues have negatively affected DOH billing processes and DOH has | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort | Project Management | Issue | Medium | Open | | D Macdonald |
| | 9/30/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that | issues have negatively affected DOH billing | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has | Project Management | Issue | Medium | Open | | D Macdonald |
| | 9/30/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to | Project Management | Issue | Medium | Open | | D Macdonald |
| | 3/30/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited | issues have negatively affected DOH billing processes and DOH has stated these are the most | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes | Project Management | Issue | Medium | Open | | Diviaccionald |
| | 3/30/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality | Project Management | Issue | Medium | Open | | Diviaccionald |
| | 3/30/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to | Project Management | Issue | Medium | Open | | Diviaccionald |
| | 3/30/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior | Project Management | Issue | Medium | Open | | Diviaccionald |
| | 3/30/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior to development being initiated. IV&V will | Project Management | Issue | Medium | Open | | D Macconato |
| | 3/30/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior to development being initiated. IV&V will continue to monitor this medium priority | Project Management | Issue | Medium | Open | | D Macconato |
| | 3730/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior to development being initiated. IV&V will continue to monitor this medium priority project issue. | Project Management | Issue | Medium | Open | | D Macconato |
| | 3730/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior to development being initiated. IV&V will continue to monitor this medium priority project issue. 11/30/2020 Quality issues persist as | Project Management | Issue | Medium | Upen | | D Macconard |
| | 3730/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior to development being initiated. IV&V will continue to monitor this medium priority project issue. 11/30/2020 Quality issues persist as approximately nine (9) new defects were found | Project Management | Issue | Medium | Upen | | D Macconard |
| | 3/30/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior to development being initiated. IV&V will continue to monitor this medium priority project issue. 11/30/2020 Quality issues persist as approximately nine (9) new defects were found in Release 3.10. RSM has acknowledged the | Project Management | Issue | Medium | Open | | D Macconard |
| | 3/30/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior to development being initiated. IV&V will continue to monitor this medium priority project issue. 11/30/2020 Quality issues persist as approximately nine (9) new defects were found in Release 3.10. RSM has acknowledged the quality concerns and inclusive of their weekly | Project Management | Issue | Medium | Open | | D Macconard |
| | 3/30/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior to development being initiated. IV&V will continue to monitor this medium priority project issue. 11/30/2020 Quality issues persist as approximately nine (9) new defects were found in Release 3.10. RSM has acknowledged the quality concerns and inclusive of their weekly status reporting have stated they are | Project Management | Issue | Medium | Open | | D Macconato |
| | 3730/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior to development being initiated. IV&V will continue to monitor this medium priority project issue. 11/30/2020 Quality issues persist as approximately nine (9) new defects were found in Release 3.10. RSM has acknowledged the quality concerns and inclusive of their weekly status reporting have stated they are incorporating additional testing considerations | Project Management | Issue | Medium | Open | | Б Массолато |
| | 3730/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior to development being initiated. IV&V will continue to monitor this medium priority project issue. 11/30/2020 Quality issues persist as approximately nine (9) new defects were found in Release 3.10. RSM has acknowledged the quality concerns and inclusive of their weekly status reporting have stated they are incorporating additional testing considerations into the SIT/Regression, and UAT processes, to | Project Management | Issue | Medium | Upen | | Б Массолато |
| | 3/30/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior to development being initiated. IV&V will continue to monitor this medium priority project issue. 11/30/2020 Quality issues persist as approximately nine (9) new defects were found in Release 3.10. RSM has acknowledged the quality concerns and inclusive of their weekly status reporting have stated they are incorporating additional testing considerations into the SIT/Regression, and UAT processes, to include: | Project Management | Issue | Medium | Open | | Б Массолато |
| | 3/30/2020 | may continue to face impactful system | that affected claims were due to multi- faceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior to development being initiated. IV&V will continue to monitor this medium priority project issue. 11/30/2020 Quality issues persist as approximately nine (9) new defects were found in Release 3.10. RSM has acknowledged the quality concerns and inclusive of their weekly status reporting have stated they are incorporating additional testing considerations into the SIT/Regression, and UAT processes, to include: - Tagging Provider Portal and Consent Registry | Project Management | Issue | Medium | Open | | D Macconard |
| | 3/30/2020 | may continue to face impactful system | that affected claims were due to multifaceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior to development being initiated. IV&V will continue to monitor this medium priority project issue. 11/30/2020 - Quality issues persist as approximately nine (9) new defects were found in Release 3.10. RSM has acknowledged the quality concerns and inclusive of their weekly status reporting have stated they are incorporating additional testing considerations into the SIT/Regression, and UAT processes, to include: - Tagging Provider Portal and Consent Registry development team items affecting screens that | Project Management | Issue | Medium | Open | | D Macconato |
| | 3730/2020 | may continue to face impactful system | that affected claims were due to multifaceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior to development being initiated. IV&V will continue to monitor this medium priority project issue. 11/30/2020 Quality issues persist as approximately nine (9) new defects were found in Release 3.10. RSM has acknowledged the quality concerns and inclusive of their weekly status reporting have stated they are incorporating additional testing considerations into the SIT/Regression, and UAT processes, to include: - Tagging Provider Portal and Consent Registry development team items affecting screens that display PHI | Project Management | Issue | Medium | Open | | Б Массолато |
| | 3/30/2020 | may continue to face impactful system | that affected claims were due to multifaceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.10 and validate that | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior to development being initiated. IV&V will continue to monitor this medium priority project issue. 11/30/2020 Quality issues persist as approximately nine (9) new defects were found in Release 3.10. RSM has acknowledged the quality concerns and inclusive of their weekly status reporting have stated they are incorporating additional testing considerations into the SIT/Regression, and UAT processes, to include: - Tagging Provider Portal and Consent Registry development team items affecting screens that display PHI - Adding negative test steps to Test Cases to | Project Management | Issue | Medium | Open | | Б Массолато |
| | 3/30/2020 | may continue to face impactful system | that affected claims were due to multifaceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.10 and validate that enhanced quality processes, including | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior to development being initiated. IV&V will continue to monitor this medium priority project issue. 11/30/2020 Quality issues persist as approximately nine (9) new defects were found in Release 3.10. RSM has acknowledged the quality concerns and inclusive of their weekly status reporting have stated they are incorporating additional testing considerations into the SIT/Regression, and UAT processes, to include: - Tagging Provider Portal and Consent Registry development team items affecting screens that display PHI - Adding negative test steps to Test Cases to verify minimum necessary data visibility when | Project Management | Issue | Medium | Open | | D Macconard |
| | 3/30/2020 | may continue to face impactful system | that affected claims were due to multifaceted quality issues were individually addressed during this reporting period. IV&V notes that there is one remaining defect still being evaluated that affects a limited number of claims. Overall, the Project Team has responded with a commitment to increase project quality and is in the process of identifying improvements to associated testing processes. These currently include: Performing Revenue Neutrality Testing to ensure expected revenue streams are largely unchanged from one period to the next. Conducting System Integration Testing, User Acceptance Testing, Performance Testing, and Regression Testing for Release 3.10. IV&V will continue to monitor the testing efforts throughout the balance of Release 3.10 and validate that | issues have negatively affected DOH billing processes and DOH has stated these are the most impactful defects | continue to pursue and/or consider: 1) Perform revenue neutrality fiscal balance testing on a quarterly basis to ensure revenues are as expected. 2) Performing typical project testing including System Integration, User Acceptance, Performance, and Regression Testing. 3) Assigning a dedicated resource to provide oversight of CAMHD Fiscal Processes. 4) BHA and RSM to collaborate on the necessary revisions to the submitted design deliverables to increase level of detail and quality - Completed 5) Monitor implemented improvements for | quality concerns and has initiated weekly meetings with the development and test teams in order to increase the quality assurance effort of each release going forward. This effort has expanded to more of a team approach to managing quality for releases and includes efforts to further develop the quality components of all user stories and requests to ensure the test goals are well known by all prior to development being initiated. IV&V will continue to monitor this medium priority project issue. 11/30/2020 Quality issues persist as approximately nine (9) new defects were found in Release 3.10. RSM has acknowledged the quality concerns and inclusive of their weekly status reporting have stated they are incorporating additional testing considerations into the SIT/Regression, and UAT processes, to include: - Tagging Provider Portal and Consent Registry development team items affecting screens that display PHI - Adding negative test steps to Test Cases to | Project Management | Issue | Medium | Open | | D Macconard |

| 46.000 | 40/5/2020 | N | | | 10/04/0000 11/01/1 | | | |
|--------|------------|---|---|--|---|--------------------|---------|-------------|
| 16.000 | 10/5/2020 | Usage of Semantics and IDM for development | | | 12/31/2020 - IV&V is aware that an overview of | Targeted KT | Concern | D Macdonald |
| | | and ongoing maintenance of the system | more targeted knowledge transfer of | | the Semantics Layer KT session was held on | | | |
| | | requires BHA to take a proactive approach to | both the Semantics Reporting and IDM | | 12/16/20. The planning effort will result in | | | |
| | | support of these tools. | tools. IV&V will continue to monitor | | additional Semantic Layer and IDM KT sessions | | | |
| | | | this concern. | | in the coming months. IV&V will continue to | | | |
| | | | | | monitor this finding. | | | |
| | | | | | 11/30/2020 - The project conducted two high- | | | |
| | | | | | level overview sessions of the Semantic Layer | | | |
| | | | | | Reporting tools during November. One session | | | |
| | | | | | was focused on the overall Semantic Layer, and | | | |
| | | | | | the second session was focused on Semantic | | | |
| | | | | | | | | |
| | | | | | Layer Security. Additional targeted Knowledge | | | |
| | | | | | Transfer sessions on the Semantic Layer tools | | | |
| | | | | | will need to be provided by RSM; however, | | | |
| | | | | | these have not been scheduled. IV&V will | | | |
| | | | | | continue to monitor this finding. | | | |
| | | | | | 10/31/2020 - The project intends to obtain | | | |
| | | | | | more targeted knowledge transfer for both the | | | |
| | | | | | Semantics Reporting and IDM tools and will be | | | |
| | | | | | planning and scheduling these sessions with the | | | |
| | | | | | RSM team in the near future. IV&V will continue | | | |
| | | | | | to monitor this concern. | | | |
| | | | | | to monitor this concern. | | | |
| | | | | | | | | |
| 17.000 | 10/27/2020 | The bandwidth of CAMHD Leadership is being | CAMHD has been provided with an | CAMDH Leadership | 12/31/2020 - The planning effort for the | Project Management | Concern | D Macdonald |
| | ' ' | hampered by planning tasks and activities for | • | participation in key | expansion of the case management solution to | , , | | |
| | | assessing project expansion to other divisions. | efforts for expansion of the project for | l' ' | the other DOH divisions continued during | | | |
| | | assessing project expansion to other divisions. | Terrores for expansion of the project for | activities could be | 1 | | | |
| | | | VUVU and VIVID & HEH CVIVID | cignificantly hindored by | IDocombor CAMHD Loadorchia continuos to | | 1 | |
| I | | | ADAD and AMHD & HSH. CAMHD | significantly hindered by | December. CAMHD Leadership continues to | | | |
| ı | | | Leadership currently spends 25% of | the flood of activities that | dedicate approximately 25% of available time | | | |
| | | | Leadership currently spends 25% of their available time dedicated to this | the flood of activities that could occur as the | dedicate approximately 25% of available time to this planning effort and it is anticipated that | | | |
| | | | Leadership currently spends 25% of | the flood of activities that could occur as the department assesses | dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in | | | |
| | | | Leadership currently spends 25% of their available time dedicated to this | the flood of activities that could occur as the department assesses expansion of this project | dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in the coming months. On the positive side, | | | |
| | | | Leadership currently spends 25% of their available time dedicated to this | the flood of activities that could occur as the department assesses | dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in the coming months. On the positive side, CAMHD leadership time dedicated to the COVID | | | |
| | | | Leadership currently spends 25% of their available time dedicated to this | the flood of activities that could occur as the department assesses expansion of this project | dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in the coming months. On the positive side, | | | |
| | | | Leadership currently spends 25% of their available time dedicated to this | the flood of activities that could occur as the department assesses expansion of this project | dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in the coming months. On the positive side, CAMHD leadership time dedicated to the COVID | | | |
| | | | Leadership currently spends 25% of their available time dedicated to this | the flood of activities that could occur as the department assesses expansion of this project | dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in the coming months. On the positive side, CAMHD leadership time dedicated to the COVID response decreased during December. IV&V will | | | |
| | | | Leadership currently spends 25% of their available time dedicated to this | the flood of activities that could occur as the department assesses expansion of this project | dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in the coming months. On the positive side, CAMHD leadership time dedicated to the COVID response decreased during December. IV&V will continue to monitor this concern. | | | |
| | | | Leadership currently spends 25% of their available time dedicated to this | the flood of activities that could occur as the department assesses expansion of this project | dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in the coming months. On the positive side, CAMHD leadership time dedicated to the COVID response decreased during December. IV&V will continue to monitor this concern. 11/30/2020 - The planning effort for the expansion of the case management solution to | | | |
| | | | Leadership currently spends 25% of their available time dedicated to this | the flood of activities that could occur as the department assesses expansion of this project | dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in the coming months. On the positive side, CAMHD leadership time dedicated to the COVID response decreased during December. IV&V will continue to monitor this concern. 11/30/2020 - The planning effort for the expansion of the case management solution to the other DOH divisions project continued. | | | |
| | | | Leadership currently spends 25% of their available time dedicated to this | the flood of activities that could occur as the department assesses expansion of this project | dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in the coming months. On the positive side, CAMHD leadership time dedicated to the COVID response decreased during December. IV&V will continue to monitor this concern. 11/30/2020 - The planning effort for the expansion of the case management solution to the other DOH divisions project continued. CAMHD Leadership continues to dedicate | | | |
| | | | Leadership currently spends 25% of their available time dedicated to this | the flood of activities that could occur as the department assesses expansion of this project | dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in the coming months. On the positive side, CAMHD leadership time dedicated to the COVID response decreased during December. IV&V will continue to monitor this concern. 11/30/2020 - The planning effort for the expansion of the case management solution to the other DOH divisions project continued. CAMHD Leadership continues to dedicate approximately 25% of available time to this | | | |
| | | | Leadership currently spends 25% of their available time dedicated to this | the flood of activities that could occur as the department assesses expansion of this project | dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in the coming months. On the positive side, CAMHD leadership time dedicated to the COVID response decreased during December. IV&V will continue to monitor this concern. 11/30/2020 - The planning effort for the expansion of the case management solution to the other DOH divisions project continued. CAMHD Leadership continues to dedicate approximately 25% of available time to this planning effort, and it is anticipated that the | | | |
| | | | Leadership currently spends 25% of their available time dedicated to this | the flood of activities that could occur as the department assesses expansion of this project | dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in the coming months. On the positive side, CAMHD leadership time dedicated to the COVID response decreased during December. IV&V will continue to monitor this concern. 11/30/2020 - The planning effort for the expansion of the case management solution to the other DOH divisions project continued. CAMHD Leadership continues to dedicate approximately 25% of available time to this planning effort, and it is anticipated that the level of effort will likely continue to increase in | | | |
| | | | Leadership currently spends 25% of their available time dedicated to this | the flood of activities that could occur as the department assesses expansion of this project | dedicate approximately 25% of available time to this planning effort and it is anticipated that the level of effort will continue to increase in the coming months. On the positive side, CAMHD leadership time dedicated to the COVID response decreased during December. IV&V will continue to monitor this concern. 11/30/2020 - The planning effort for the expansion of the case management solution to the other DOH divisions project continued. CAMHD Leadership continues to dedicate approximately 25% of available time to this planning effort, and it is anticipated that the | | | |

| 18 | 3.000 | 11/30/2020 | Due to consistent technical issues requiring | The IDM and Semantic layer efforts | | IV&V recommends the project to continue to | 12/31/2020 - While most of the issues requiring | Release/Deployment | Issue | Medium | Open | D Macdonald |
|----|-------|------------|---|--|---------------------------|---|---|--------------------|----------|----------|------|--------------|
| 10 | | | | have experienced several delays | | monitor the status of outstanding Microsoft | escalation to Microsoft were adequately | Planning | 13300 | iviculum | Ореп | Diviacuonalu |
| | | | Layer project efforts are being delayed. | attributable to issues escalated to | | tickets and to escalate the priority of these | addressed during December, the Azure Data | I idilling | | | | |
| | | | Edych project chorts are being delayed. | Microsoft. The issues have ranged | | tickets as deemed necessary. | Factory (ADF) 'first 10 rows missing data' issue | | | | | |
| | | | | from administrative / communication | | tickets as decined necessary. | remain open. BHA has created a work around | | | | | |
| | | | | (entering issues into the Commercial | | | for this issue while awaiting a permanent and | | | | | |
| | | | | support instance vs the Government | | | reliable resolution from Microsoft. Additionally, | | | | | |
| | | | | Cloud support instance), to several key | | | the Project awaits the "Datalake" function fix | | | | | |
| | | | | technical issues requiring assistance to | | | from Microsoft to address a priority IDM issue. | | | | | |
| | | | | resolve. To date, these support needs | | | The fix was intended to be delivered the end of | | | | | |
| | | | | have added over a month to the IDM | | | 2020 but that did not pan out. No new target | | | | | |
| | | | | and Semantic Layer project schedules. | | | date has been provided by Microsoft. IV&V will | | | | | |
| | | | | and Semantic Layer project schedules. | | | continue to monitor this issue in January. | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | 11/30/2020 - The IDM and Semantic layer | | | | | |
| | | | | | | | efforts have experienced several delays | | | | | |
| | | | | | | | attributable to issues escalated to Microsoft. The issues have ranged from | | | | | |
| | | | | | | | | | | | | |
| | | | | | | | administrative/communication (entering issues | | | | | |
| | | | | | | | into the Commercial support instance vs the | | | | | |
| | | | | | | | Government Cloud support instance) to several | | | | | |
| | | | | | | | key technical issues requiring assistance to | | | | | |
| | | | | | | | resolve. To date, these support needs have | | | | | |
| | | | | | | | added over a month to the IDM and Semantic | | | | | |
| | | | | | | | Layer project schedules. | | | | | |
| | | | | | | | | | | | | |
| 19 | .000 | 12/31/2020 | Due to on-going deployment processes and | There have been several defects | Repeatable documented | Develop a plan to institutionalize the | 12/31/2020 - Release 3.11 was promoted to | Release/Deployment | Issue | Medium | Open | D Macdonald |
| | | | technical execution issues, the project may | pushed to production with Phase 3 | release and deployment | execution of "Smoke Testing" for promotions | production on 12/13/2020. The promotion to | Planning | | | | |
| | | | continue to encounter defects and challenges | releases. Some of the defects | will help ensure that | to non-production and production | the test environment for final testing and | | | | | |
| | | | in meeting projected timelines for production | introduced to production have been | mistakes are minimized, | environments. This will help to ensure that | execution of regression test scripts prior to | | | | | |
| | | | and non-production deployments. | narrowed down to environmental | and that functionality is | all components needed to test have been | production deployment was missing software | | | | | |
| | | | | promotional activities. In these | not mistakenly deprecated | properly deployed prior to the actual | components. As a result, several user stories | | | | | |
| | | | | instances, the DEV and TEST | when deployments take | execution of test activities. | and defects were not tested as planned and | | | | | |
| | | | | environments were not in sync with | place. | Work in collaboration with RSM to establish a | were excluded from the production | | | | | |
| | | | | the production environment (missing | | plan for DOH to assume all deployment | deployment. These items were subsequently re- | | | | | |
| | | | | business rules, missing components, | | activities to ensure complete ownership of | prioritized to be resolved in a Mid Sprint | | | | | |
| | | | | missing dependencies, etc.). IVV is | | these processes. This should assist with | Deployment in mid January or R3.12 in | | | | | |
| | | | | aware that DOH staff shadowed RSM | | consistency in approach and execution going | February. | | | | | |
| | | | | staff for all deployment releases | | forward. | | | | | | |
| | | | | during Phase 2 with RSM providing | | As appropriate, consult with RSM on best | | | | | | |
| | | | | instruction and DOH staff physically | | practices that BHA could employ to support | | | | | | |
| 1 | | | | executing the tasks and activities via | | deployment. | | | | | | |
| | | | | keyboard. For Phase 3, it is unclear | | Look at implementing 'hard' code freeze | | | | | | |
| | | | | whether a complete, up to date, and | | dates as well as test environment | | | | | | |
| | | | | documented deployment script, or | | deployment dates to ensure that testing and | | | | | | |
| | | | | deployment notes, are being utilized | | deployment activities are not rushed. | | | | | | |
| | | | | by BHA for deployment activities. | | COMPLETED | | | | | | |
| | | | | | | Request the assistance of the RSM Solution | | | | | | |
| | | | | | | Architect in reviewing and correcting issues | | | | | | |
| | | | | | | associated with consistency of the | | | | | | |
| | | | | | | configurations across environments, ensuring | | | | | | |
| | | | | | | that the test environment is capable of | | | | | | |
| | | | | | | testing ALL functions of any given release | | | | | | |
| | | | | | | without the need for using multiple test | | | | | | |
| | | | | | <u> </u> | | | | <u> </u> | | | |